Weight-Loss Drug Wegovy Lowers Major Heart Disease Risk By 20% According To Trial Data—Novo Nordisk Shares Surge

The weight-loss drug Wegovy lowers the risk of “adverse cardiovascular events” by 20%, according to data from a major trial shared by the drug’s maker Novo Nordisk Tuesday, causing the company’s shares to surge.... [+]press release

, Novo Nordisk said that a weekly 2.4 milligram dose of semaglutide—the generic name for Wegovy, which is also sold under the name “Ozempic”—resulted in a 20% reduction in heart attacks and strokes. The trial measured data over a period of five years and involved 17,604 participants aged 45 or older who were either overweight or obese.

The trial also found that the 2.4 mg dosage was “safe and well-tolerated” in line with previous similar trials. The announcement of the trial results caused the drug maker’s Copenhagen-listed shares to surge by more than 16% on Tuesday, before settling at around 13.4% in the green during afternoon trading.This is a developing story.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Source: Reuters - 🏆 2. / 97 Read more »